Israel - English - Ministry of Health

teva israel ltd - paclitaxel - concentrate for solution for infusion - paclitaxel 6 mg/ml - paclitaxel - paclitaxel - ovarian carcinoma : paclitaxel teva is indicated alone or in combination for the treatment of advanced carcinoma of the ovary. breast carcinoma : * paclitaxel teva is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin - containing combination chemotherapy. * paclitaxel teva is indicated for the treatment of metastatic breast cancer after failure of combination chemotherapy. prior therapy should have included an anthracycline unless clinically contraindicated. advanced non small cell lung cancer : paclitaxel teva associated with cisplatium is indicated for the treatment of non small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy. kaposis sarcoma : paclitaxel teva is indicated in the second- line treatment of aid's related kaposi's sarcoma.

Israel - English - Ministry of Health

salomon,levin & elstein ltd - paclitaxel - concentrate for solution for infusion - paclitaxel 6 mg/ml - paclitaxel - paclitaxel - ovarian carcinoma : paclitaxel teva is indicated alone or in combination for the treatment of advanced carcinoma of the ovary. breast carcinoma : paclitaxel teva is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin - containing combination chemotherapy. paclitaxel teva is indicated for the treatment of metastatic breast cancer after failure of combination chemotherapy. prior therapy should have included an anthracycline unless clinically contraindicated. advanced non small cell lung cancer : paclitaxel teva associated with cisplatium is indicated for the treatment of non small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy. kaposis sarcoma : paclitaxel teva is indicated in the second- line treatment of aid's related kaposi's sarcoma. gastric carcinoma : paclitaxel teva for the treatment of advanced gastric carcinoma.

United States - English - NLM (National Library of Medicine)

gland pharma limited - paclitaxel (unii: p88xt4is4d) (paclitaxel - unii:p88xt4is4d) - paclitaxel 6 mg in 1 ml - paclitaxel injection, usp is indicated as subsequent therapy for the treatment of advanced carcinoma of the ovary. as first-line therapy, paclitaxel is indicated in combination with cisplatin. paclitaxel is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy. in the clinical trial, there was an overall favorable effect on disease-free and overall survival in the total population of patients with receptor-positive and receptor-negative tumors, but the benefit has been specifically demonstrated by available data (median follow-up 30 months) only in the patients with estrogen and progesterone receptornegative tumors. (see clinical studies: breast carcinoma. ) paclitaxel injection, usp is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. prior therapy should have included an anthracycline unless cl

United States - English - NLM (National Library of Medicine)

teva parenteral medicines, inc. - paclitaxel (unii: p88xt4is4d) (paclitaxel - unii:p88xt4is4d) - paclitaxel 6 mg in 1 ml - paclitaxel injection is indicated as subsequent therapy for the treatment of advanced carcinoma of the ovary. as first-line therapy, paclitaxel injection is indicated in combination with cisplatin. paclitaxel injection is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy. in the clinical trial, there was an overall favorable effect on disease-free and overall survival in the total population of patients with receptor-positive and receptor-negative tumors, but the benefit has been specifically demonstrated by available data (median follow-up 30 months) only in the patients with estrogen and progesterone receptor-negative tumors (see clinical studies, breast carcinoma ). paclitaxel injection is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. prior therapy should have included an anthracycline unl

United States - English - NLM (National Library of Medicine)

teva parenteral medicines, inc. - paclitaxel (unii: p88xt4is4d) (paclitaxel - unii:p88xt4is4d) - paclitaxel 6 mg in 1 ml - paclitaxel injection is indicated as subsequent therapy for the treatment of advanced carcinoma of the ovary. as first-line therapy, paclitaxel injection is indicated in combination with cisplatin. paclitaxel injection is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy. in the clinical trial, there was an overall favorable effect on disease-free and overall survival in the total population of patients with receptor-positive and receptor-negative tumors, but the benefit has been specifically demonstrated by available data (median follow-up 30 months) only in the patients with estrogen and progesterone receptor-negative tumors (see clinical studies, breast carcinoma ). paclitaxel injection is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. prior therapy should have included an anthracycline unl

United States - English - NLM (National Library of Medicine)

mylan institutional llc - paclitaxel (unii: p88xt4is4d) (paclitaxel - unii:p88xt4is4d) - paclitaxel 30 mg in 5 ml - paclitaxel injection is indicated as subsequent therapy for the treatment of advanced carcinoma of the ovary. as first-line therapy, paclitaxel injection is indicated in combination with cisplatin. paclitaxel injection is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy. in the clinical trial, there was an overall favorable effect on disease-free and overall survival in the total population of patients with receptor-positive and receptor-negative tumors, but the benefit has been specifically demonstrated by available data (median follow-up 30 months) only in the patients with estrogen and progesterone receptor-negative tumors (see clinical studies, breast carcinoma ). paclitaxel injection is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. prior therapy should have included an anthracycline unl

United States - English - NLM (National Library of Medicine)

actavis pharma, inc. - paclitaxel (unii: p88xt4is4d) (paclitaxel - unii:p88xt4is4d) - paclitaxel 6 mg in 1 ml - paclitaxel injection, usp is indicated as subsequent therapy for the treatment of advanced carcinoma of the ovary. as first-line therapy, paclitaxel injection, usp is indicated in combination with cisplatin. paclitaxel injection, usp is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy. in the clinical trial, there was an overall favorable effect on disease-free and overall survival in the total population of patients with receptor-positive and receptor-negative tumors, but the benefit has been specifically demonstrated by available data (median follow-up 30 months) only in the patients with estrogen and progesterone receptor-negative tumors (see clinical studies, breast carcinoma). paclitaxel injection, usp is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. prior therapy should have included a

United States - English - NLM (National Library of Medicine)

wg critical care, llc - paclitaxel (unii: p88xt4is4d) (paclitaxel - unii:p88xt4is4d) - paclitaxel 6 mg in 1 ml - paclitaxel injection, usp is indicated as subsequent therapy for the treatment of advanced carcinoma of the ovary. as first-line therapy, paclitaxel injection, usp is indicated in combination with cisplatin. paclitaxel injection, usp is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy. in the clinical trial, there was an overall favorable effect on disease-free and overall survival in the total population of patients with receptor-positive and receptor-negative tumors, but the benefit has been specifically demonstrated by available data (median follow-up 30 months) only in the patients with estrogen and progesterone receptor-negative tumors (see clinical studies, breast carcinoma ). paclitaxel injection, usp is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. prior therapy should have included

United States - English - NLM (National Library of Medicine)

breckenridge pharmaceutical, inc. - paclitaxel (unii: p88xt4is4d) (paclitaxel - unii:p88xt4is4d) - paclitaxel 30 mg in 5 ml - paclitaxel injection, usp is indicated as subsequent therapy for the treatment of advanced carcinoma of the ovary. as first-line therapy, paclitaxel is indicated in combination with cisplatin. paclitaxel is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy. in the clinical trial, there was an overall favorable effect on disease-free and overall survival in the total population of patients with receptor-positive and receptor-negative tumors, but the benefit has been specifically demonstrated by available data (median follow-up 30 months) only in the patients with estrogen and progesterone receptornegative tumors (see clinical studies, breast carcinoma ). paclitaxel injection, usp is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. prior therapy should have included an anthracycline unless clinica

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - paclitaxel (unii: p88xt4is4d) (paclitaxel - unii:p88xt4is4d) - paclitaxel 6 mg in 1 ml - paclitaxel injection, usp is indicated as subsequent therapy for the treatment of advanced carcinoma of the ovary. as first-line therapy, paclitaxel injection, usp is indicated in combination with cisplatin. paclitaxel injection, usp is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy. in the clinical trial, there was an overall favorable effect on disease-free and overall survival in the total population of patients with receptor-positive and receptor-negative tumors, but the benefit has been specifically demonstrated by available data (median follow-up 30 months) only in the patients with estrogen and progesterone receptor-negative tumors (see clinical studies, breast carcinoma ). paclitaxel injection, usp is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. prior therapy should have included